Publication Name	World Journal of Hepatology
Manuscript ID	11345
Country	Japan

Received	2014-05-16 21:22
Peer-Review Started	2014-05-18 23:24
To Make the First Decision	2014-06-27 12:02
Return for Revision	2014-07-04 12:19
Revised	2014-07-16 23:28
Second Decision	2014-08-31 16:59
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-08-31 17:16
Articles in Press	2014-08-31 17:17
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-09-30 16:17
Publish the Manuscript Online	2014-10-19 20:39

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Masako Shomura, Tatehiro Kagawa, Koichi Shiraishi, Shunji Hirose, Yoshitaka Arase, Jun Koizumi and Tetsuya Mine
Funding Agency and Grant Number	Funding Agency Grant Number Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Young Scientists (B) 21792240
Corresponding Author	Masako Shomura, RN, PhD, Associate Professor, Department of Nursing, Tokai University School of Health Sciences, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan. rocky36j@is.icc.u-tokai.ac.jp
Key Words	Hepatocellular carcinoma; Molecular targeted therapy; Drug toxicity; Surrogate marker; Nursing intervention
Core Tip	Sorafenib therapy for advanced hepatocellular carcinoma (HCC) often causes adverse events (AEs), subsequently leading to dose reduction or discontinuation. Conversely, few studies have associated serious AEs with a favorable response to sorafenib. We aimed to elucidate the relationship between AEs occurrence, therapeutic efficacy, and the impact of nursing intervention on adherence to therapy. We observed that skin toxicity was associated with favorable outcomes in sorafenib therapy for advanced HCC. Furthermore nursing intervention contributed to better adherence, which may improve the efficacy of sorafenib therapy.
Publish Date	2014-10-19 20:39
Citation	Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, Koizumi J, Mine T. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol 2014; 6(9): 670-676
URL	http://www.wjgnet.com/1948-5182/full/v6/i9/670.htm
DOI	http://dx.doi.org/10.4254/wjh.v6.i9.670

Full Article (PDF)	WJH-6-670.pdf
Full Article (Word)	WJH-6-670.doc
Manuscript File	11345-Review.docx
Answering Reviewers	11345-Answering reviewers.pdf
Copyright License Agreement	11345-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	Ethics_Committee_20140516205039.pdf
Non-Native Speakers of English Editing Certificate	11345-Language certificate.pdf
Peer-review Report	11345-Peer review(s).pdf
Scientific Misconduct Check	11345-CrossCheck.jpg
Scientific Editor Work List	11345-Scientific editor work list.pdf